31.10.2013 Official Journal of the European Union L 289/49 COMMISSION REGULATION (EU) No 1066/2013 of 30 October 2013 refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods ('), and in particular Article 18(5) thereof, Whereas: 1 Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims. Regulation (EC) No 19242006 also provides that appli- cations for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’ for a scientific assessment, as well as to the Commission and the Member States for information. The Authority is to deliver an opinion on the health claim concerned. The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority. Following an application from Béres Pharmaceuticals Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of gluco- samine and maintenance of joints (Question No EFSA-Q- 2011-00907) (3). The claim proposed by the applicant was worded as follows: ‘Glucosamine contributes to the protection of joint cartilage exposed to excessive motion or loading and helps to improve the range of motion in joints’. On 5 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of glucosamine and the () OJ L 404, 30.12.2006, p. 9. (%) EFSA Journal 2011; 9(12):2476. (10) (11) claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. Following an application from Merck Consumer Healthcare, submitted pursuant to Article 13(5) of Regu- lation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of glucosamine and maintenance of normal joint cartilage (Question No EFSA-Q-2011-01113) (*). The claim proposed by the applicant was worded, inter alia, as follows: ‘Glucosamine contributes to the maintenance of normal joint cartilage’. On 16 May 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of glucosamine and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. Following an application from Extraction Purification Innovation France, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of wheat polar lipid extract and protection of the skin against dehydration (Question No EFSA-Q-2011-01122) (. The claim proposed by the applicant was worded, inter alia, as follows: ‘Con- tributes to improve skin hydration’. On 5 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of wheat polar lipid extract and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. Following an application from Lesaffre International/ Lesaffre Human Care, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Saccharomyces cerevisiae var. boulardii CNCM 1-3799 and reducing gastro-intestinal discomfort (Question No EFSA-Q-2012-00271) (°). The claim proposed by the applicant was worded as follows: ‘Sac- charomyces cerevisiae var. boulardii CNCM 1-3799 helps maintain intestinal comfort’. (®) EFSA Journal 2012; 10(5):2691. (*) EFSA Journal 2012; 10(7):2773. (°) EFSA Journal 2012; 10(7):2801.